Skip to search formSkip to main contentSkip to account menu

Pharmacokinetic study

Known as: PHARMACOKINETIC, PK Study, pharmacokinetic studies 
A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.
National Institutes of Health

Related topics

Related topics

3 relations
CDISC SDTM Trial Type TerminologyClinical Data Interchange Standards Consortium TerminologyRadioligand Assay

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
AIMS AND OBJECTIVES Variations in drug metabolizing genes are known to have a clinical impact on AED therapy. We genotyped normal… 
2014
2014
Discovery of SCH 900188: A Potent Hepatitis C Virus NS5B Polymerase Inhibitor Prodrug As a Development Candidate.
Starting from indole-based hepatitis C virus (HCV) NS5B polymerase inhibitor lead compound 1, structure modifications were… 
2013
2013
An Evaluation of Calcilytic Effects on Parathyroid Hormone and Bone Mineral Density Response Using a Physiologically-Based, Multiscale Systems Pharmacology Model
ABSTRACT Recent research involving Ca sensing receptor (CaSR) antagonists (calcilytics) has focused on assimilating transient… 
2008
2008
The Pharmacokinetic (PK) Interaction Between Tenofovir Disoproxil Fumarate (TDF) and the Investigational HCV Protease Inhibitor Telaprevir (TVR)
2008
2008
Population pharmacokinetic (PK) analysis of gefitinib in pediatric cancer patients
2523 Background: Gefitinib is an orally active inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase… 
2007
2007
Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide
BACKGROUND: Population pharmacokinetic (PK) and pharmacodynamic (PK/PD) models based on early Phases 1 and 2 data for the new… 
2006
2006
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors
PurposeTo assess the maximum tolerated dose, safety, and pharmacokinetic (PK) profile of escalating doses of the novel… 
2006
2006
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
INTRODUCTION Ibandronate is a potent, nitrogen-containing bisphosphonate that is licensed as a once-monthly oral preparation and… 
1999
1999
Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines… 
Review
1999
Review
1999
Brain tryptophan/serotonin perturbations in metabolic encephalopathy and the hazards involved in the use of psychoactive drugs.
Several combined pathogenetic factors such as hyperammonemia, different brain tryptophan metabolic disturbances and serotonin…